New study aims to unlock genetic secrets of colorectal cancer in hispanic communities
NCT ID NCT06063928
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study enrolls 500 Hispanic adults with colorectal cancer to collect genetic and clinical data. Researchers hope to learn why some patients respond better to treatments than others. The goal is to pave the way for personalized medicine, where treatments are tailored to each person's genetic makeup.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could help doctors match colorectal cancer treatments to each patient's unique genetics, leading to more personalized care.
- What could go wrong
- This is an observational study, not a treatment trial. It may not directly improve outcomes, and results may take years to apply in practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 500 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2022
- Expected to finish
-
May 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Self-reported Hispanic ethnicity * Diagnosed with colon or rectal cancer (at any time and stage; lifetime diagnosis and in survival are eligible) * Has a tumor tissue sample archived or plans to have tissue archived from a standard care procedure * Age \>= 18 years * Ability to understand and the willingness to sign a written informed consent. * For those who would like to participate in the optional microbiome characterization aspect of the study, the patient will have to be under 40 years old at any clinical cancer stage or over 60 years old at any clinical cancer stage. Exclusion Criteria: * Inability to understand and the willingness to sign a written informed consent
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Colorectal cancer are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Los Angeles County-USC Medical Center
RECRUITINGLos Angeles, California, 90033, United States
-
USC / Norris Comprehensive Cancer Center
RECRUITINGLos Angeles, California, 90033, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Ivosidenib plus mFOLFOXIRI and celecoxib as a treatment for BRAF-targeted therapy-refractory BRAF V600E-mutant colorectal cancer patients: a phase II study
- Can a new drug shrink advanced solid tumors?
- Can a new drug shrink tumors that resist standard care?
- A single blood draw to detect five cancers before symptoms appear?
- Can a new drug duo shrink Hard-to-Treat tumors?
- Could a simple mineral calm the Body's Post-Surgery fire?